| 70-gene signature as an aid to treatment decisions in early-stage breast cancer F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ... New England Journal of Medicine 375 (8), 717-729, 2016 | 1856 | 2016 |
| Short-course radiation plus temozolomide in elderly patients with glioblastoma JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ... New England Journal of Medicine 376 (11), 1027-1037, 2017 | 1005 | 2017 |
| Lomustine and bevacizumab in progressive glioblastoma W Wick, T Gorlia, M Bendszus, M Taphoorn, F Sahm, I Harting, ... New England Journal of Medicine 377 (20), 1954-1963, 2017 | 889 | 2017 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 … MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ... The Lancet 390 (10103), 1645-1653, 2017 | 364 | 2017 |
| Switching benchmarks in cancer of unknown primary: from autopsy to microarray G Pentheroudakis, V Golfinopoulos, N Pavlidis European journal of cancer 43 (14), 2026-2036, 2007 | 315 | 2007 |
| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 304 | 2020 |
| Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis V Golfinopoulos, G Salanti, N Pavlidis, JPA Ioannidis The lancet oncology 8 (10), 898-911, 2007 | 233 | 2007 |
| Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 … MJ van den Bent, CMS Tesileanu, W Wick, M Sanson, AA Brandes, ... The Lancet Oncology 22 (6), 813-823, 2021 | 173 | 2021 |
| INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma M Van Den Bent, M Eoli, JM Sepulveda, M Smits, A Walenkamp, ... Neuro-oncology 22 (5), 684-693, 2020 | 160 | 2020 |
| Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG DT Blumenthal, T Gorlia, MR Gilbert, MM Kim, L Burt Nabors, WP Mason, ... Neuro-oncology 19 (8), 1119-1126, 2017 | 143 | 2017 |
| Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis V Golfinopoulos, G Pentheroudakis, G Salanti, AD Nearchou, ... Cancer treatment reviews 35 (7), 570-573, 2009 | 143 | 2009 |
| Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation … W Wick, T Gorlia, P Bady, M Platten, MJ Van Den Bent, MJB Taphoorn, ... Clinical cancer research 22 (19), 4797-4806, 2016 | 139 | 2016 |
| Evaluating novel agent effects in multiple‐treatments meta‐regression G Salanti, S Dias, NJ Welton, AE Ades, V Golfinopoulos, M Kyrgiou, ... Statistics in medicine 29 (23), 2369-2383, 2010 | 117 | 2010 |
| Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study JC Reijneveld, MJB Taphoorn, C Coens, JEC Bromberg, WP Mason, ... The Lancet Oncology 17 (11), 1533-1542, 2016 | 116 | 2016 |
| Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the … K Draaisma, A Chatzipli, M Taphoorn, M Kerkhof, A Weyerbrock, ... Journal of Clinical Oncology 38 (1), 81-99, 2020 | 108 | 2020 |
| Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial MJ van den Bent, M Klein, M Smits, JC Reijneveld, PJ French, P Clement, ... The Lancet Oncology 19 (9), 1170-1179, 2018 | 106 | 2018 |
| LB-05 phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial W Wick, AA Brandes, T Gorlia, M Bendszus, F Sahm, W Taal, M Taphoorn, ... Neuro-oncology 17 (suppl_5), v1-v1, 2015 | 103 | 2015 |
| Serial FDG–PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy A Hendlisz, V Golfinopoulos, C Garcia, A Covas, P Emonts, L Ameye, ... Annals of oncology 23 (7), 1687-1693, 2012 | 91 | 2012 |
| Treatment of colorectal cancer in the elderly: a review of the literature V Golfinopoulos, G Pentheroudakis, N Pavlidis Cancer treatment reviews 32 (1), 1-8, 2006 | 75 | 2006 |
| EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. W Wick, AA Brandes, T Gorlia, M Bendszus, F Sahm, W Taal, ... Journal of Clinical Oncology 34 (15_suppl), 2001-2001, 2016 | 72 | 2016 |
